(L-R) Bill Haney, Tyler Jacks, Ph.D., and David Raulet, Ph.D., co-founders of @dragonflytx, whose TriNKET platform will be used by @Merck to develop solid tumor #Cancer #immunotherapies: http://ow.ly/TbR530m2SPP
More From BioPortfolio on "(L-R) Bill Haney, Tyler Jacks, Ph.D., and David Raulet, Ph.D., co-founders of @dragonflytx, whose TriNKET platform will be used by @Merck to develop solid tumor #Cancer #immunotherapies: http://ow.ly/TbR530m2SPP "